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Lauric acid is a medium-chain fatty acid that has been reported to possess anti-inflammatory, 
antioxidant and antibacterial properties. Diabetic complication in the lungs is characterized by 
infiltration of inflammatory mediators and structural alteration of the lung parenchyma. This 
study was designed to evaluate the effect of lauric acid on leucocytes infiltration in 
bronchoalveolar lavage fluid (BALF), concentration of tumor necrosis factor-α and lung 
histology of type II diabetic male Wistar rats. A total of thirty-five male Wistar rats were 
randomly divided into seven groups of five rats each as follows: Group I served as normal 
control; group II were normoglycemic rats, administered 125 mg/Kg bwt lauric acid. Group III 
served as diabetic control. Groups IV, V, VI and VII were diabetic Wistar rats treated with 125 
mg/Kg bwt, 250 mg/Kg bwt, 500 mg/Kg bwt lauric acid and 100 mg/Kg bwt metformin 
respectively. The results obtained, showed a significant (P ≤ 0.05) increase in total white blood 
cell count and differential count of lymphocytes, neutrophils and macrophages in blood and 
BALF of the diabetic control compared to the normal control. However, there was a significant 
decrease in total and differential white blood cell count in blood and BALF of the diabetic groups 
treated with lauric acid compared to the diabetic control (P ≤ 0.05). The concentration of TNF-
α was significantly higher in the lungs of diabetic rats compared to the normal control, but the 
concentration was significantly reduced after treatment with lauric acid (P ≤ 0.05). Lauric acid 
also reversed the reduced alveolar spaces in diabetic lungs. These results indicate that lauric acid 
reduced inflammation and reversed the histoarchitectural alterations in the lungs of type II 
diabetic male Wistar rats. 
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INTRODUCTION   
Diabetes mellitus is a metabolic disorder characterized 
by chronic hyperglycemia caused by absolute or relative 
insulin deficiency, resulting in metabolic consequences 
of impaired carbohydrates, proteins and lipids 
metabolisms (Keerthi et al., 2012). It is the most 
common of all endocrine diseases and is a threat to both 
young and old due to its increasing prevalence and 
associated disabling complications (IDF, 2017). Type II 
diabetes forms about 90% of all diabetes cases, making 
it the most common type and the main driver of the 





adult population with almost 80% from developing 
countries (WHO, 2016). 
Pulmonary complications of diabetes which are also 
called diabetic pneumopathy, have been reported for 
many decades, however, because the lung microvascular 
system has huge reserve function, diabetic lung damage 
is quite subclinical and often ignored (Kapoor et al., 
2015; Almeida et al., 2016). The association between 
impaired lung function and diabetes is thought to be the 
result of biochemical changes in the structures of the 
lung tissue and airways that involves a series of 
mechanisms likely due to systemic inflammation, 
oxidative stress, hypoxemia and the direct damage 
caused by chronic hyperglycemia (Rogliani et al., 2015). 
The impaired lung functions in patients with diabetes 
appears to be inversely related to blood glucose levels, 
duration of disease and its severity. A histological 
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investigation of diabetic rabbit lungs revealed that, the 
diabetic lungs exhibited morphological abnormalities 
associated with an intense inflammatory reaction, 
characterized by massive inflammatory cell infiltration, 
within 3 weeks of diabetes induction (Zheng et al., 
2017). The structural changes in diabetic lungs have 
been described by Kuziemsky et al. (2011), as 
thickening of walls of pulmonary alveoli caused by 
elevated levels of collagen and elastin; thickening of a 
basal membrane of alveoli, and elastic recoil ability; 
thickening of basal membrane of capillaries and 
endothelium. Diabetes mellitus complication in the 
lungs is also associated with recruitment and infiltration 
of macrophages, neutrophils and other inflammatory 
cells into the lung tissues (Moral-Sanz et al., 2012). The 
mechanism of cellular infiltration into the lungs in 
diabetes may be due to systemic inflammation induced 
by lipotoxicity, which triggered toll-like receptors 
activation on free fatty acid sensing (Lynch et al., 2014). 
The infiltrating macrophages expresses peroxisome 
proliferator activated receptor gamma (PPARγ), and also 
produce inflammatory cytokines such as interleukin-1β, 
interleukin-6 and tumor necrosis factor-a, which play a role 
in mediating inflammatory responses (Cho et al., 2014; 
Chen et al., 2015). 
Lauric acid is a saturated fatty acid that is found in many 
vegetable oils and fats, particularly in coconut oil, palm 
kernel oil and laurel oil. A significant component of 
saturated fatty acid found in human breast milk was 
reported to consist of lauric acid (Aly et al., 2013). It is one 
of the most active ingredient of coconut oil, and composed 
of over 52% of the total 92% saturated fats present in 
coconut oil. It has 12 carbon atom chain, thus making it 
a medium chain fatty acid with a molecular formula: C12 
H24 O2 (Uday et al., 2014; Anzaku et al., 2017). 
Although a saturated fatty acid, lauric acid was reported 
to have decreased the mRNA expression of 
apolipoprotein, decrease low density lipoprotein (LDL) 
levels, but raise high density lipoprotein (HDL) levels, 
such that the total cholesterol level decline (Arunima and 
Rajamohan, 2018). Studies have shown that lauric acid 
was responsible for the pharmacological properties of 
coconut oil such as antioxidant (Alves et al., 2017), anti-
hyperlipidemic, anti-inflammatory, and antimicrobial 
properties (Dayrit, 2015). This study was therefore 
designed to evaluate the potential benefits of lauric acid 
on leucocytes infiltration in BALF, concentration of 
TNF-α, and lung histology of type II diabetic male 
Wistar rats. 
 
MATERIALS AND METHODS 
Drugs and Reagents 
Lauric acid (CAS-NO:143-07-7) and Streptozotocin 
(STZ) were obtained from Sigma Aldrich (USA), Simas 
Margarine was purchased from PT Salim Ivomas 
Pratama Tbk, (Indonesia), Rats Enzyme-linked 
immunosorbent assay (ELISA) kits TNF-α was 
purchased from Wuhan Fine Biotech Co. Ltd (China), 
Fructose (20% w/v) was purchased from Kem Light 
Laboratories PVT Ltd (India), Metformin was purchased 
from Jiangsu Ruinian Qianjin Pharmaceutical Co. Ltd 
(China). Other reagents used were of analytical grade 





Thirty-five (35) apparently healthy male Wistar rats 7-8 
weeks old, weighing 80-100g, were purchased from the 
National Veterinary Research Institute, Vom, Plateau 
State, Nigeria. The animals were housed in the Animal 
House of Department of Human Physiology, Faculty of 
Basic Medical Sciences, Ahmadu Bello University, 
Zaria, Nigeria. They were provided with Grower’s mash 
and water ad libitum and were acclimatized to the 
laboratory conditions for two weeks. The experimental 
protocol was reviewed and certified by Ahmadu Bello 
University committee on Animal Use and Care 
(ABUCAUC), with approval number 
(ABUCAUC/2018/071). Strict adherence to the Ethical 
Committee’s directives was observed. 
 
Preparation of High Fat Diet and Induction of Type II 
Diabetes Mellitus 
High fat diet (HFD) preparation and induction of type II 
diabetes were done according to the method of Okoduwa 
et al. (2017) with some modifications. Normal diet feed 
(NDF) containing: 18% Fats, 28% Proteins, 54% 
Carbohydrates, was mixed with Simas margarine: 99.9% 
Fats, groundnut mill: 46.2% Fats, 25.2% Proteins, 
21.3% Carbohydrates and ground nut oil: 100% Fats. 
The HFD was constituted by mixing 10 grams of NDF 
with 2.5 grams Simas margarine, 2.5 grams of groundnut 
mill and 1 gram of ground nut oil. The nutrient 
composition of the prepared HFD was 41% Fats, 22% 
Proteins and 37% Carbohydrates. The animals were fed 
with the HFD along with 20% fructose solution as 
drinking water for six weeks, after which they were 
fasted overnight and injected intraperitoneally with a 
single, low dose of streptozotocin (STZ), at a dose of 40 
mg/kg diluted in 0.1 M citrate-buffered saline (pH 4.5). 
The normal control rats were also injected with equal 
volumes of citrate-buffered saline. The rats were 
provided 5% glucose solution as drinking water in the 
first 24 hours after STZ injection. Diabetes was 
confirmed by determining blood glucose concentrations 
72 hours after STZ administration, while the validation 
of diabetes was done one week after initial confirmation, 
and rats with fasting blood glucose levels ≥ 300 mg/dl 
were considered diabetic. 
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Table 1: Effect of Lauric Acid on the Mean Total and Differential White Blood Cell Counts in the Bronchoalveolar 
Lavage Fluid (BALF) of Type II Diabetic Male Wistar Rats. 
 
 
Results are presented as Mean ± Standard Error of Mean of five (5) rats. Values with superscript are significant at 
P≤0.05.  a= When compared to the normal control, b= When compared to the diabetic control. NC= Normal control, NG= 




Animal Grouping and Treatment 
After the induction of type II diabetes mellitus, the rats 
were divided into seven (7) groups of 5 rats each.  Lauric 
acid was dissolved in tween 80 (vehicle) at a ratio of 1:2 
(w/v) and diluted to desired concentrations in distilled 
water. 
 
Group I (Normal control): Normoglycemic rats 
administered 1ml/Kg bwt distilled water orally. once 
daily for three weeks. 
Group II: Normoglycemic rats administered 125 mg/Kg 
bwt Lauric acid orally, once daily for three weeks. 
Group III (Diabetic control): Diabetic rats administered 
1ml/Kg bwt tween 80 orally, once daily for three weeks. 
Group IV: Diabetic rats administered 125 mg/Kg bwt of 
Lauric acid orally, once daily for three weeks.  
Group V: Diabetic rats administered 250 mg/Kg bwt of 
Lauric acid orally, once daily for three weeks. 
Group VI: Diabetic rats administered 500 mg/Kg bwt of 
Lauric acid orally, once daily for three weeks. 
Group VII: Diabetic rats administered 100 mg/Kg bwt 
Metformin, orally, once daily for three weeks  
 
Determination of Blood Glucose Level  
Blood was obtained from tail vein, and blood glucose 
level was determined using glucose test strips and digital 
glucometer based on glucose oxidase principle (Rheney 
and Kirk, 2000).  
 
Sample Collection 
At the end of the three (3) weeks treatment period, the 
rats were fasted overnight, and then anaesthetized with 
50mg/Kg Ketamine hydrochloride. Blood samples were 
then collected via cardiac puncture using 5ml syringes 
and were stored in EDTA bottles which was used for 
total and differential white blood cell count. 
 
Collection of Broncho Alveolar Fluid (BALF) 
Broncho Alveolar lavage procedure was performed 
surgically in an anesthetized rat. 2ml of normal saline 
was infused into the lungs through the trachea by means 
of a cannula. The fluid was rinsed and aspirated 30 
seconds later. The procedure was repeated, and the 
collected fluid was centrifuged at 3000 x g for 10 
minutes. The subnatant was used for total and 
differential white blood cell count (Chaudhari et al., 
2011). 
 
Preparation of Lung Homogenate 
Lung homogenate was prepared from the left lung. The 
lung was removed, weighed and homogenized with 
phosphate buffered saline (140 mM KCl, 20 mM 
phosphate, pH 7.4). Every one gram of lung tissue was 
homogenized with 9ml of phosphate buffer. The 
homogenate was centrifuged at 9000 ×g for 30 min and 
the supernatant was used for measurement of TNF-α 
concentration (Samarghandian et al., 2014). 
 
 Hematological Analysis 
Total white blood cell counts in blood and BALF were 
determined using hemocytometeric method and were 
counted using light microscope with X10 magnification 
while the differential white blood cells were counted 
using a magnification of X100 (Cheesbrough, 1999). 
 
Biochemical Assay of TNF-α 
The assay for the tumor necrosis factor-alpha 
concentration, was carried out using rat TNF-α ELISA 
Kit according to manufacturer's instruction.  
 
 Histological Studies of Lung Tissue 
The right lungs were used for histological studies, using 
H and E staining technique as described by Bancroft and 
Stevens (1990). The slides were examined with light 
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microscope at a magnification of X100 and 
photomicrographs taken.  
 
Statistical Analysis 
Statistical Package for Social Sciences (SPSS) version 
20 was used for data analysis. Data are expressed as 
mean + Standard Error of Mean (SEM). Statistical 
significance of differences was assessed using one-way 
analysis of variance (ANOVA), followed by a Tukey’s 
post-hoc test for multiple comparisons between groups. 




Table 1 shows the effect of lauric acid on the total and 
differential white blood cell count in BALF of diabetic 
rats. There was a significant increase in total WBC and 
differential count of lymphocytes, neutrophils and 
macrophages in the diabetic control compared to their 
respective counts in the normal control (P≤0.05). 
However, after treatment of the diabetic rats with 125 
mg/Kg bwt, 250 mg/Kg bwt and 500 mg/Kg bwt lauric 
acid as well 100 mg/Kg bwt Metformin, there was a 
significant decrease in total WBC and differential counts
 
 
Table 2: Effect of Lauric Acid on the Mean Total and Differential White Blood Cell Counts in the Blood of Type II 
Diabetic Male Wistar Rats. 
 
Results are presented as Mean ± Standard Error of Mean of five (5) rats. Values with superscript are significant at P≤0.05.  a= 
When compared to the normal control, b= When compared to the diabetic control. NC= Normal control, NG= Normoglycemic, 
DW= Distilled water, DC=Diabetic control, TW=Tween 80, LA= lauric acid, DB= Diabetes, Met= Metformin  
 
when compared to diabetic control (P≤0.05), except for 
250 mg/Kg bwt Lauric acid and 100 mg/Kg bwt 
Metformin treated groups which did not significantly 
reduce the differential count of neutrophils and in 
addition, 250 mg/Kg bwt Lauric acid did not also 
significantly reduce the total WBC count compared to 
diabetic control (P>0.05). The normoglycemic rats 
treated with 125 mg/Kg bwt lauric acid, did not show 
any significant difference for total WBC, lymphocytes, 
neutrophils and macrophages counts when compared to 
the normal control (P>0.05), however, there was a 
significant decrease in lymphocytes, neutrophils and 
macrophages counts when compared to their respective 
counts in the diabetic control (P≤0.05). 
 
 
In Table 2, the effect of lauric acid on the mean total 
and differential white blood cell count in the blood of 
type II diabetic male Wistar rats shows that the mean 
total WBC count in the diabetic control was significantly 
increased when compared to normal control (P≤0.05). 
The total WBC and differential count of lymphocytes, 
neutrophils and monocytes of normoglycemic rats 
treated with 125 mg/Kg bwt lauric acid, diabetic rats 
treated with 125 mg/Kg bwt and 500 mg/Kg bwt lauric 
acid, were significantly reduced when compared to the 
diabetic control (P≤0.05), except for diabetic rats treated 
with 125mg/Kg bwt lauric acid which did not show 
significant difference in differential count of 
lymphocytes compared to diabetic control (P>0.05). The 
mean total and differential WBC counts in diabetic rats 
treated with 250 mg/kg lauric acid showed no significant 
difference when compared to diabetic control (P>0.05). 
Diabetic rats treated with 100 mg/Kg bwt Metformin 
only showed significant decrease in differential count of 
neutrophils and monocytes when compared with 
diabetic control (P≤0.05). 
 
The result in Figure 1 shows the effect of lauric acid 
on the mean concentration of TNF-α in the lungs of type 
II diabetic male Wistar rats. The concentration of TNF-
α in diabetic control was significantly increased at 
P≤0.05 compared to the normal control. Normoglycemic 
rats group treated with 125 mg/Kg bwt lauric acid has a 
significantly lower concentration of TNF-α when 
compared with diabetic control (P≤0.05). However, it 
did not show significant difference when compared with 
normal control (P>0.05). There was a significant 
decrease in the concentrations of TNF-α in the diabetic 
rats treated with 125 mg/Kg bwt, 500 mg/Kg bwt lauric 
acid and 100 mg/Kg bwt metformin when compared 
with diabetic control (P≤0.05). The concentration of 
TNF-α in the diabetic rats treated with 250 mg/Kg bwt 
lauric acid did not show significant difference when 
compared to diabetic control (P>0.05). 
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Fig.1: Effect of Lauric Acid on the Mean Concentration of 
Tumor Necrosis Factor Alpha (TNF-α) in the Lungs of Type 
II Diabetic Male Wistar Rats. Results are presented as Mean 
± Standard Error of Mean of five (5) rats. Values with 
superscript are significant at P≤0.05.  a= When compared to 
the normal control, b= When compared to the diabetic control. 
NC= Normal control, NG= Normoglycemic, DW= Distilled 
water, DC=Diabetic control, TW=Tween 80, LA= lauric acid, 
DB= Diabetes, Met= Metformin 
 
Fig. 2 shows the lung photomicrograph of the normal 
control and normoglycemic rats treated with 125mg/Kg 
bwt lauric acid, showing normal alveolar sac with no 
cellular infiltration and no significant pathological 
changes in the bronchial epithelium. Although, the lungs 
of normoglycemic rats treated with 125 mg/Kg bwt 
lauric acid showed mild cellular infiltration. There were 
obvious histopathological changes in the lungs of the 
diabetic control rats, characterized by thickened alveolar  
basement membrane, massive cellular infiltration and 
distorted bronchial epithelium. Treatment of diabetic 
rats with 125 mg/kg bwt, 250 mg/kg bwt and 500 mg/kg 
bwt lauric acid reduced the cellular infiltration in the 
lungs, and replacement with normal alveolar sac and 
bronchial epithelium. However, diabetic rats treated 
with 125 mg/Kg bwt lauric acid showed mild cellular 
infiltration in the lungs with congestion, but no obvious 
pathological changes. Lungs of diabetic rats treated with 
100 mg/Kg bwt metformin had a normal bronchial 




Fig. 2: Photomicrographs of lung tissues of Normoglycemic/ 
Diabetic Wistar rats Treated with Lauric Acid. (H and E, 
Magnification X 100). (a) Normal control rats with normal 
alveolar spaces without cellular infiltration. (b) NG+125 mg/Kg 
bwt LA: Normoglycemic rats treated with 125mg/Kg bwt lauric 
acid histological section shows normal alveolar spaces but with 
mild cellular infiltration. (c) Diabetic control shows massive 
cellular infiltration and distorted bronchial epithelium with 
thickened alveolar basement membrane. (d) DB+125 mg/Kg bwt 
LA: Diabetic rats treated with 125mg/Kg bwt lauric acid, Mild 
cellular infiltration with lungs with congestion, but no obvious 
pathological changes in the alveolar. (e) DB+250 mg/Kg bwt LA: 
Diabetic rats treated with 250mg/Kg bwt lauric acid, Mild cellular 
infiltration with normal alveolar spaces. (f) DB+500 mg/Kg bwt 
LA: Diabetic rats treated with 500mg/Kg bwt lauric acid, Mild 
cellular infiltration with normal alveolar spaces. (g) 
DB+100mg/Kg bwt Met: Diabetic rats treated with 100mg/Kg 




Diabetic pulmonary complication termed ‘diabetic 
pneumopathy’, is a glucotoxicity-induced complication 
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caused by chronic hyperglycemia. This complication 
leads to a reduction in lung function that is characterized 
by systemic inflammation-associated recruitment and 
infiltration of inflammatory cells and proinflammatory 
cytokines in the lung tissues (Niazi et al., 2013). This 
study evaluated the effect of lauric on leucocytes 
infiltration in BALF, concentration of TNF-α and lung 
histology of type II diabetic male Wistar rats. 
In the present study, it was observed that high fat diet-
streptozotocin-induced type II diabetes mellitus caused 
a significant cellular infiltration into the lung tissues. 
This was characterized by increase in total WBC, 
lymphocytes, neutrophils and macrophages counts 
BALF as well as the blood of the diabetic rats. This 
result is consistent with the findings of a study by Neto 
et al. (2013), who reported increased pulmonary 
microvascular permeability and inflammatory cell 
infiltration within pulmonary tissues in diabetic rats. The 
increased differential and total WBC count in BALF 
may be secondary to the increase in the blood as seen in 
this study. Pulmonary alveolar macrophages (PAMs), 
derived from circulating monocytes, are the major 
resident phagocytic cells in the lungs. Together with 
neutrophils, they mediate first line of defense, as such, 
their number is usually increased in diabetes-associated 
lung inflammation. The PAMs exert their phagocytic 
activity in the lungs, through a mechanism related to the 
activation of Fc gamma receptors (Cheung et al., 2000). 
Once activated, PAMs initiate inflammatory responses 
and recruit activated neutrophils into the alveolar spaces, 
and also release reactive intermediates such as 
superoxide ions and proinflammatory cytokines which 
play a significant role in the pathogenesis of immune 
complex mediated lung injury (Rubins, 2003). However, 
contrary to this result, Alba-Loureira et al. (2007), 
reported that alloxan-induced diabetes is associated with 
reduced number of leucocyte count, impaired 
inflammatory processes such as chemotaxis, 
phagocytosis and generation of superoxide ions by both 
neutrophils and macrophages. Besides macrophages and 
neutrophils, lymphocyte count was also increased in 
both BALF and blood of diabetic rats. Lymphocytes, 
particularly the CD4+ have been reported to be recruited 
to the lungs in response to pulmonary infection (Xia et 
al., 2017).  
Treatment of diabetic rats with lauric acid in this 
study, significantly decreased the number of total and 
differential leucocytes count in the blood, and inhibited 
their infiltration into the lungs. Lauric acid was reported 
to inhibit the up-regulatory effect of interferon gamma 
(IFN-γ), which is a T-helper cell 1 produced cytokine 
that serves as a potent activator of macrophages during 
the innate and acquired immune response (Lim et al., 
2015). Therefore, reduction in IFN-γ may consequently 
cause a decrease in the number of macrophages that 
infiltrate the lungs, as shown in this study. Lauric acid 
has also been shown to possess antimicrobial activity, 
and has been reported to be effective in relieving 
inflammation caused by bacteria, viruses and fungi 
through inhibition of infiltration of neutrophils and 
macrophage inflammatory protein-2 to the site of the 
inflammation, as well as inhibition of TLR2 mediated 
production of pro-inflammatory cytokines (Nakatsuji et 
al., 2009; Anzaku et al., 2017). Lauric acid did not 
significantly affect the total and differential leucocyte 
count of lymphocytes, neutrophils and macrophages in 
the lungs of normoglycemic rats compared to the normal 
control. This implies that, the ability of lauric acid to 
exert its anti-inflammatory action by decreasing the 
number of total and differential white blood cells 
infiltrating the diabetic lungs, may be dependent on the 
existence of lung inflammation. Despite the fact that all 
the three doses of lauric acid reduced the infiltration of 
inflammatory cells into the lungs, the higher dose of 500 
mg/Kg was shown to be the most effective while 250 
mg/Kg dose the least effective. This occurred in spite of 
the fact that, all the three doses significantly decreased 
the mean fasting blood glucose level of diabetic rats in 
the same degree as metformin, a standard antidiabetic 
agent. Because metformin decreased the total and 
differential white blood cells count in blood and also 
inhibited their infiltration into the lungs, it implies that, 
lauric acid might have mediated its action of decreasing 
the number of infiltrating leucocytes, through a 
mechanism that may be related to its blood glucose 
lowering action. 
This study also showed an increase in the 
concentration of tumor necrosis factor -alpha (TNF-α), 
in the lungs of diabetic rats. The result is substantiated 
by the findings of studies conducted by Eren et al. 
(2010), and Zhang et al. (2015), who also reported an 
elevation in the concentration of TNF-α in the lungs of 
diabetic rats. Tumor necrosis factor-α is a 
proinflammatory cytokine, that at higher concentration 
leads to exacerbation of inflammatory and prooxidative 
responses, that are important in the pathogenesis of 
various pulmonary disorders (Patel et al., 2013). Tumor 
necrosis factor-α mediated inflammatory responses are 
activated via Nuclear factor kappa B (NF-κB) signaling 
pathways, which play an important role in broad 
spectrum of inflammatory networks that regulate 
cytokine activity in the lungs, activated by toll-like 
receptors 2 and 4 subtypes (TLR2 and TLR4) (Dasu et 
al., 2012; Schuliga, 2015). The TNF-α released from this 
inflammatory pathway, plays a crucial role in triggering 
alveolar epithelial dysfunction, leading to pulmonary 
edema, through activation of its p55 receptor–mediated 
death signaling involving caspase-8 (Patel et al., 2013). 
Lauric acid treated diabetic rats, showed a 
significant reduction in the concentration of TNF-α in 
their lung tissues. In agreement with this result, 
Nishimura et al. (2018), reported that lauric acid 
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decreased TLR4-mediated production of 
proinflammatory cytokines, TNF-α, IL-1β, and IL-6, 
associated with neuroinflammatory responses by 
activated microglia, via GPR40-dependent signaling 
cascade. However, contrary to the result of this study, 
Wang et al. (2018), reported that lauric acid activates 
TLR4 to facilitate the recruitment of myeloid 
differentiation primary response 88 (MyD88) and 
eventually promote nuclear translocation of NF-κB, 
leading to the expression of inflammatory genes that 
mediate inflammatory responses.  Nuclear factor kappa 
B pathway and the mitogen activated protein 
kinase/extracellular signal-regulated kinase 
(MAPK/ERK) cascades, have been proposed as the two 
major mechanisms for modulation of the production of 
pro-inflammatory molecules like TNF-α and IL-1β 
(Huang et al., 2014), These pathways which are 
prominent contributors to chronic inflammatory 
responses, have been shown to be suppressed by 
treatment with lauric acid.  
The mechanism of anti-inflammatory action of 
lauric acid on TNF-α concentration in the diabetic lungs 
may be related to the activation of peroxisomal 
proliferator activated-receptor gamma (PPARγ), which 
is a member of the nuclear hormone receptor 
superfamily that plays an important role in the regulation 
of inflammatory and immune reactions. Lauric acid may 
through PPARγ, protects against inflammation by its 
ability to mediate suppression of TLR activation, pro-
inflammatory transcription factor, NF-κB activation and 
inhibition of pro-inflammatory mediators like TNF-α, 
while increasing the production of anti-inflammatory 
cytokines such as IL-4 and IL-10 (Dasu et al., 2012; 
Kortekaas et al., 2013). A study by Liberato et al. 
(2012), reported lauric acid as a partial agonist of PPAR-
γ, and may through its binding to PPAR- γ, decrease the 
concentration of TNF-α in diabetic lungs, by inhibiting 
the expression of TLR and NF-κB inflammatory 
signaling pathways. The upregulation of PPAR-γ was 
reported to cause an increased expression of interleukin-
10 (IL-10), an anti-inflammatory cytokine that 
suppresses the level of proinflammatory cytokine TNF- 
α and interleukin-6 (Munoz and Costa, 2013). This may 
be another mechanism via which lauric acid exerts its 
anti-inflammatory action. Lauric acid at lower dose of 
125 mg/Kg bwt and higher dose of 500 mg/Kg bwt and 
metformin at 100 mg/Kg bwt were shown to 
significantly reduced the level of TNF- α in the diabetic 
lungs, unlike 250mg/kg, lauric acid which did not 
significantly reduce the level of TNF- α in the diabetic 
lungs. 
In this study, and as in a previous study by Suarez et 
al. (2016), the histology of the diabetic lungs, showed 
the presence of inflammatory cells, increased thickness 
of alveolocapillary basement membrane and decreased 
alveolar surface area. The mechanism of diabetic lung 
injury was hypothesized to be hyperglycemia-induced 
upregulation of a variety of pathways including; NF-κB 
inflammatory pathway, oxidative stress and non-
enzymatic glycosylation of proteins of the lungs (Zheng 
et al., 2017). Excessive non-enzymatic glycosylation of 
proteins of the lungs, impaired the cross-links of 
collagen and elastin, thus, decreasing both their strength 
and elasticity Suarez et al., 2016). Increased thickness of 
the alveolo-capillary barrier and the expansion of the 
interstitium are associated with a reduction of alveolar 
space and narrowing of the pulmonary capillary 
network. These alterations contribute to a reduction in 
gas diffusion velocity through the alveolo-capillary 
membrane (Pitocco et al., 2012). Treatment with lauric 
acid was shown to significantly reduce the level of 
infiltration of inflammatory cells into the lung tissues 
and also reduced the thickening of the alveolo-capillary 
basement membrane. The mechanism by which lauric 
acid was able to alleviate diabetic lung injury, may be 
related to its ability to exert anti-inflammatory action 




Lauric acid exerts potent anti-inflammatory properties 
that are effective in ameliorating biochemical and 
structural changes in the lungs induced by type II 
diabetes mellitus.   
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